Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study

Rodrigo Alonso · Ana M. Camon · Celia Cardozo · Laia Albiach · Daiana Agüero · M. Angeles Marcos · Juan Ambrosioni · Marta Bodro · Mariana Chumbita · Lorena de la Mora · Nicole Garcia-Pouton · Gerard Dueñas · Marta Hernandez-Meneses · Alexy Inciarte · Genoveva Cuesta · Fernanda Meira · Laura Morata · Pedro Puerta-Alcalde · Sabina Herrera · Montse Tuset · Pedro Castro · Sergio Prieto-Gonzalez · Josep Mensa · José Antonio Martínez · Gemma Sanjuan · J. M. Nicolas · A. del Rio · Jordi Vila · Felipe García · Carolina Garcia-Vidal · Alex Soriano (on behalf of Hospital Clinic of Barcelona COVID-19 research group)

Received: December 29, 2021 / Accepted: March 10, 2022 / Published online: April 27, 2022 © The Author(s) 2022

ABSTRACT

Introduction: Increased mortality has been reported in the Latin American population. The objective is to compare the clinical
characteristics and outcome of Latin American and Spanish populations in a cohort of patients
hospitalized with COVID-19 during the first year of the pandemic.

Methods: We retrospectively analysed all the Latin American patients (born in South or
Central America) hospitalized in our centre from February 2020 to February 2021 and
compared them with an age- and gender-matched group of Spanish subjects. Variables
included were demographics, co-morbidities, clinical and analytical parameters at admission
and treatment received. The primary outcomes were ICU admission and mortality at 60 days. A
conditional regression analysis was performed

Rodrigo Alonso and Ana M. Camon: contributed equally.

Members of “Hospital Clinic of Barcelona COVID-19 Research Group” are listed in the Acknowledgements section.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s40121-022-00623-x.

R. Alonso · A. M. Camon · C. Cardozo · L. Albiach · D. Agüero · J. Ambrosioni · M. Bodro · M. Chumbita · L. de la Mora · N. Garcia-Pouton · G. Dueñas · M. Hernandez-Meneses · A. Inciarte · F. Meira · L. Morata · P. Puerta-Alcalde · S. Herrera · J. Mensa · J. A. Martínez · G. Sanjuan · A. del Rio · F. García · C. Garcia-Vidal · A. Soriano

Department of Infectious Diseases, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona, C/Villarroel 170, 08036 Barcelona, Spain
e-mail: asoriano@clinic.cat

M. A. Marcos · G. Cuesta · J. Vila

Department of Microbiology, Hospital Clinic of Barcelona, University of Barcelona, Institute for Global Health (ISGlobal), Barcelona, Spain

M. Tuset

Department of Pharmacy, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain

P. Castro · J. M. Nicolas

Medical Intensive Care Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain

S. Prieto-Gonzalez

Department of Internal Medicine, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain

G. Sanjuan

Computer System Unit, Hospital Clinic, Barcelona, Spain
to evaluate the independent baseline predictors of both outcomes.

Results: From the 3216 patients in the whole cohort, 216 pairs of case-controls (Latin American and Spanish patients, respectively) with same age and gender were analysed. COPD was more frequent in the Spanish group, while HIV was more prevalent in the Latin American group. Other co-morbidities showed no significant difference. Both groups presented with similar numbers of days from symptom onset, but the Latin American population had a higher respiratory rate (21 vs. 20 bpm, \(P = 0.041\)), CRP (9.13 vs. 6.22 mg/dl, \(P = 0.001\)), ferritin (571 vs. 383 ng/ml, \(P = 0.012\)) and procalcitonin (0.10 vs. 0.07 ng/ml, \(P = 0.020\)) at admission and lower cycle threshold of PCR (27 vs. 28.8, \(P = 0.045\)). While ICU admission and IVM were higher in the Latin American group (17.1% vs. 13% and 9.7% vs. 5.1%, respectively), this was not statistically significant. Latin American patients received remdesivir and anti-inflammatory therapies more often, and no difference in the 60-day mortality rate was found (3.2% for both groups).

Conclusion: Latin American patients with COVID-19 have more severe disease than Spanish patients, requiring ICU admission, antiviral and anti-inflammatory therapies more frequently. However, the mortality rate was similar in both groups.

Keywords: COVID-19; Latin American population; Mortality; Spanish population

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been detected worldwide, with > 4 million related deaths [1]. Several risk factors have been associated with worse outcome including host-dependent factors including age, gender and co-morbidities (chronic heart disease, chronic kidney disease and obesity), genetic traits of the immune response pathway responsible for control respiratory virus replication and virological factors such as the infecting variant or exposure to a high viral load from the index case [2]. These factors are associated with the development of a dysregulated immune response leading to complications such us pneumonia, acute respiratory distress syndrome (ARDS), pulmonary thrombosis and finally death [3]. Recently, three reports from the US described a significant increase in the mortality rate among the Latin American population. One, from Los Angeles County, described an age-adjusted mortality rate (AAMR) due to COVID-19 among Latinx individuals of 160.1 deaths per 100,000 patients.
compared with 51.7 deaths per 100,000 patients among White individuals [4]. Another, performed in Florida, presented death rates of 86.8 and 39.3 per 100,000 patients for Latinx and White individuals, respectively [5]. The third, from 99 counties within 14 US states, compared non-Hispanic white persons with other populations. The Latin American population had a higher hospitalization, ICU admission and death rates [6]. These results suggest a role in the origin in COVID-19 outcomes, although it could also just be an association due to poor resources of this population compared to the White one. Indeed, a larger study from Veteran Affairs Hospitals across the US did not observe different mortality rates among the Latin American population compared to White individuals, although the clinical presentation and biomarkers were not evaluated, and consequently it was not possible to adjust the mortality rate according to the severity of the infection [7].

The Latinx population living in Spain is large, and they receive the same quality of care from the Public Health Services as that provided for the native Spanish people. Accordingly, we have performed a matched case-control study to compare the clinical presentation and outcome of Latin American and Spanish patients with COVID-19 admitted to our tertiary university hospital from February 2020 to February 2021. We hypothesized that Latin Americans have higher inflammatory response than Spaniards.

METHODS

Study Design and Patients

This matched case-control study was performed at the Hospital Clinic in Barcelona, Spain, a 700-bed university centre that provides care for an urban population of 500,000 adults. All patients admitted for ≥ 48 h with confirmed rRT-PCR tests performed with nasopharyngeal throat swabs or clinical pictures highly suggestive of COVID-19 between 18 February 2020 and 24 February 2021 were included. Deaths occurring within the first 48 h were included in the analysis. The Institutional Ethics Committee of the Hospital Clinic of Barcelona approved the study, and due to the nature of the retrospective data review, they waived the need for informed consent from individual patients (HCB/2020/0273). This corresponds to the same number as in previous articles from our group because the project included the analysis of different variables associated with COVID-19 outcomes. The Institutional Ethics Committee of Hospital Clinic of Barcelona approved the study and, due to the nature of the retrospective data review, waived the need for informed consent from individual patients (HCB/2020/0273). The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.

Patients who were born in any country from South or Central America were identified as members of the Latin American group, whereas those born in Spain were considered Spaniards.

Data Collection

Data were retrospectively collected for all patients included in the study from the electronic health records (EHRs). An intelligent system was used to retrieve the high-quality data from EHRs (SILDv1.0 system, S34M®) as previously described [8]. Variables included were: age, gender, pre-admission duration of symptoms in days, co-morbidities (hypertension, chronic heart disease, diabetes mellitus, chronic liver disease, chronic kidney disease, chronic obstructive pulmonary disease, haematological and solid neoplasia), respiratory rate and ambient air arterial oxygen saturation (SaO₂) measured with a pulse oximeter at admission, creatinine, lymphocyte count, C-reactive protein (C-RP), lactate dehydrogenase (LDH), D-dimer, ferritin and procalcitonin within the first 24 h from hospital admission. Body mass index was not available. When it was available, the cycle threshold (Ct) of the diagnostic RT-PCR test was gathered. Data on the need for ICU admission and invasive mechanical ventilation were also gathered. Data on treatment with remdesivir, tocilizumab and dexamethasone during the hospitalization were
Table 1 Characteristics of patients according to study groups

| Variable                        | Latin American group (n = 216) | Spanish group (n = 216) | P-value<sup>m</sup> |
|---------------------------------|-------------------------------|--------------------------|---------------------|
| Median (IQR) age in years       | 48 (40–58)                   | 48 (40–58)               | 1                   |
| Male gender, n (%)              | 114 (52.8)                   | 114 (52.8)               | 1                   |
| Comorbidity, n (%)              |                               |                          |                     |
| Chronic heart disease           | 21 (9.7)                     | 18 (8.3)                 | 0.615               |
| Hypertension                    | 51 (23.6)                    | 55 (25.5)                | 0.655               |
| Diabetes mellitus               | 27 (12.5)                    | 22 (10.2)                | 0.448               |
| Chronic kidney disease          | 10 (4.6)                     | 13 (6)                   | 0.520               |
| Chronic liver disease           | 19 (8.8)                     | 17 (7.9)                 | 0.728               |
| COPD                            | 3 (1.4)                      | 11 (5.1)                 | 0.030               |
| Haematological malignancy       | 7 (3.2)                      | 11 (5.1)                 | 0.336               |
| Solid neoplasm                  | 5 (2.3)                      | 12 (5.6)                 | 0.083               |
| Solid organ transplantation      | 5 (2.3)                      | 7 (3.2)                  | 0.558               |
| HIV infection                   | 16 (7.4)                     | 5 (2.3)                  | 0.014               |
| Parameters at admission         |                               |                          |                     |
| Days from symptom onset<sup>a</sup> | 7 (5–9)                  | 7 (5–9)                  | 0.943               |
| Median (IQR) respiratory rate, breaths per min<sup>b</sup> | 21 (18–24) | 20 (18–24) | 0.041 |
| Median (IQR) temperature, °C<sup>c</sup> | 37 (36.5–37.8) | 37.1 (36.5–38) | 0.716 |
| Median (IQR) percentage of oxygen saturation<sup>d</sup> | 95 (93–96) | 95 (93–96) | 0.537 |
| Median (IQR) C<sub>t</sub><sup>e</sup> | 27 (22.9–30) | 28.8 (24.6–31.4) | 0.045 |
| Median (IQR) creatinine, mg/dl<sup>f</sup> | 0.82 (0.66–0.99) | 0.81 (0.67–0.96) | 0.678 |
| Median (IQR) C-reactive protein, mg/dl<sup>g</sup> | 9.13 (4.67–15) | 6.22 (2.87–10.28) | 0.001 |
| Median (IQR) LDH, IU/ml<sup>h</sup> | 310 (258–388) | 301 (242–358) | 0.082 |
| Median (IQR) ferritin, ng/ml<sup>i</sup> | 571 (258–1142) | 383 (189–962) | 0.012 |
| Median (IQR) d-dimer, IU/l<sup>j</sup> | 500 (300–900) | 500 (400–975) | 0.079 |
| Median (IQR) procalcitonin, ng/ml<sup>k</sup> | 0.10 (0.05–0.21) | 0.07 (0.04–0.15) | 0.020 |
| Median (IQR) lymphocyte count, cells/mm<sup>3</sup><sup>l</sup> | 1000 (800–1300) | 1000 (700–1325) | 0.201 |
| Treatment                       |                               |                          |                     |
| Remdesivir                      | 56 (25.9)                    | 34 (15.7)                | 0.009               |
| Tocilizumab                     | 50 (23.1)                    | 36 (16.7)                | 0.092               |

<sup>a</sup> Adis
collected. The primary endpoints were ICU admission and mortality at 60 days.

**Statistical Analysis**

We looked for controls born in Spain with the same age and gender among the 3216 patients recorded in our previously described database [8]. No other variables were used for matching patients. The matching was performed using the SPSS tool (SPSS Inc., Chicago, IL). Categorical variables were described using the absolute number and percentage and continuous variables using the median and interquartile range (IQR). Categorical variables were compared using a chi-squared test or Fisher exact test when necessary. Continuous variables were compared using Mann-Whitney U test. A conditional regression analysis was performed to evaluate the independent baseline predictors of ICU admission and mortality at 60 days. Baseline variables included demographics, co-morbidities and biochemical parameters within the first 24 h from admission. Continuous variables were dichotomized by the median value to be included in the uni- and multivariate analyses. Variables with a *P*-value < 0.2 in the univariate analysis were included in the regression analysis. Only variables with < 10% missing values were considered for the analysis. The origin group (Latin American or Spanish) was forced to enter in the model to evaluate its potential independent influence on the outcomes. There was no imputation for missing data. Statistical significance was defined as a two-tailed *P*-value < 0.05. The analysis was performed in SPSS version 26 (SPSS Inc., Chicago, IL).

**RESULTS**

A total of 3216 patients were admitted, and 222 (6.9%) of these were born in a South or Central American country and were identified as the Latin American group. A total of 216 pairs of cases (Latin American group) and controls (Spanish group) with the same age and gender were identified and included in the study. The main demographic variables and co-morbidities are shown in Table 1. The rate of co-morbidities was similar between the two groups except for chronic obstructive pulmonary disease (COPD),
which was more frequent among the Spanish patients (5.1% [11 out of 216] vs. 1.4% [3 out of 216], \( P = 0.030 \)), and HIV infection (7.4% [16 out of 216] vs. 2.3% [5 out of 216], \( P = 0.014 \)), which was more prevalent in the Latin American group. Although the number of days from symptom onset to admission was the same between the two groups, the Latin American group had a significantly higher respiratory rate (21 versus 20 breaths per minute, \( P = 0.041 \)), and there were significant differences in the main inflammatory parameters. The median CRP (9.13 mg/dl vs. 6.22 mg/dl, \( P = 0.001 \)), ferritin (571 ng/ml vs. 383 ng/ml, \( P = 0.012 \)) and procalcitonin (0.10 ng/ml versus 0.07 ng/ml, \( P = 0.020 \)) were significantly higher in the Latin American group. The Ct value was available in 179 patients (93 from the Latin American group and 86 from the Spanish group), and its median value was significantly lower in the Latin American group (27 versus 28.8, \( P = 0.045 \)), suggesting a higher viral load.

In terms of outcome, the Latin American group required ICU admission (17.1% vs. 13%, \( P = 0.226 \)) and invasive mechanical ventilation (9.7% vs. 5.1%, \( P = 0.066 \)) more frequently, although these differences were not statistically significant. No difference in the mortality at 30 (2.8% for both groups) and 60 days (3.2% for both groups) was observed.

Variables associated with ICU admission were age, male gender, co-morbidities, oxygen saturation and inflammatory parameters (Supplementary material, Table S1). Repeating the analysis for ICU admission without age and gender showed no changes in the final model. Conditional regression analysis identified as independent baseline variables, oxygen saturation (OR, 1.424; CI 95% 1.253–1.681, \( P < 0.001 \)), creatinine > 0.82 mg/dl (OR, 1.927; CI 95% 1.007–3.690, \( P = 0.048 \)), CRP > 7.5 mg/dl (OR, 2.920; CI 95% 1.430–5.962, \( P = 0.003 \)) and D-dimer > 500 IU/l (OR, 2.047; CI 95% 3.066–1.934, \( P = 0.031 \)). The Latin American origin variable was not entered in any of the models as an independent variable. Variables associated with mortality at 60 days are shown in supplementary material (Table S2). Age and co-morbidities were the most important factors, and the conditional regression analysis selected age > 66 years (OR, 9.823; CI 95% 1.091–88.461, \( P = 0.042 \)), chronic renal failure (OR, 23.386; CI 95% 5.496–99.511, \( P < 0.001 \)) and chronic liver disease (OR, 5.420; CI 95% 1.111–26.441, \( P = 0.037 \)) as independent variables.

**DISCUSSION**

A worse outcome of COVID-19 among Latin American patients has been suggested in recent articles that compare the mortality rate in this population versus others [4]. In our hospital, 6.9% (222 out of 3216) patients were from Latin America, which is more than double the rate of officially recognized Latin American natives living in Barcelona (3%). This finding suggests that this population has a higher exposure or susceptibility to SARS-CoV-2 infection. We identified 216 pairs matched by age and gender, and the main conclusion is that Latin American patients, at the time of hospital admission, had a higher viral load (low Ct values), higher respiratory rate and higher serum concentration of inflammatory markers (C-RP, LDH, ferritin, D-dimer and procalcitonin). These differences existed even when the duration of symptoms prior to admission was the same in both origin groups. Potential explanations for a higher viral load in the Latin American group include a particular genetic trait in any of the innate immune system pathways responsible for controlling the viral replication, as has been demonstrated in adults with worse outcomes [9], or a higher frequency of autoantibodies against interferon-2α among the Latin American population [10]. Indeed, autoimmunity is more frequent and the clinical expression is more severe in this population [11]. Other explanations could be related to the exposure to a higher viral load. The exposure to an index case with a high viral load in respiratory secretions has been associated with a higher risk of developing symptomatic COVID-19 [12, 13]. The analysis of three clusters of COVID-19 that occurred in close environments showed that the severity of the new infections was inversely associated with the house size [14]. The Latin American population, according to their social
status, usually lives in small, poorly ventilated apartments, with more family members; this could explain our results in part. Of course, both hypotheses are not mutually exclusive and can be combined in the Latin American population.

The viral load of SARS-CoV-2 correlates with the inflammatory response, severity of the infection and death [15]. Inflammatory markers were significantly higher in the Latin American group, but their mortality rate, adjusted by age and gender, was not different from that of the control group. It sounds reasonable to attribute this finding to the fact that the protocol of our institution includes remdesivir [16] and anti-inflammatory therapies including tocilizumab and dexamethasone [17] from the beginning. In agreement with the clinical presentation of Latin American patients, they received remdesivir, tocilizumab and dexamethasone more frequently.

The main limitation of our study is the lack of information about anthropometric variables of the included population. The influence of obesity on the outcome of COVID-19 is well recognized, but unfortunately, we did not collect this information. The second limitation is that the Ct value was only available in approximately 40% of the included patients. However, the significantly higher inflammatory response observed in Latin Americans makes this finding reasonable. The third limitation is that we divided the group by the place of birth but not according to the ethnic group. The fourth limitation is that we included the number of days from symptom onset to hospitalization in the analysis, and the interpretation of this variable could be difficult in the elderly or it could be biased by socioeconomic factors.

CONCLUSIONS

Latin American patients living in Spain and admitted to the hospital because of SARS-CoV-2 infection had a higher viral load and inflammatory response than native Spaniards even when they had the same duration of symptoms prior to admission. Consequently, they required ICU admission, invasive mechanical ventilation, and the prescription of antiviral and anti-inflammatory therapies more frequently. Nonetheless, there were no differences in mortality in this population. In the future, to clarify the potential influence of genetics on the outcome of Latin American patients, it will be necessary to include this population in larger studies. While waiting for these results, it is important to advise the at-risk populations to implement isolation measures and room ventilation at home when an index case is declared, particularly in a crowded environment, to avoid exposure to higher viral loads and to implement adequate protocols of treatment to reduce the mortality rate.

ACKNOWLEDGEMENTS

Funding. This work was financed by ad hoc patronage funds for research on COVID-19 from donations from citizens and organizations to the Hospital Clínic de Barcelona-Fundació Clínic per a la Recerca Biomèdica, Barcelona, Spain. No funding or sponsorship was received for the publication of this article.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author contributions. Rodrigo Alonso and Ana M. Camon both were responsible for reviewing the data, and they prepared the database including the matching analysis as well as a first draft of the article. Celia Cardozo, Laia Albiach, Daiana Agüero, M. Angeles Marcos, Juan Ambrosioni, Marta Bodro, Mariana Chumbita, Lorena de la Mora, Nicole García-Pouton, Gerard Dueñas, Marta Hernández-Meneses, Alexy Inciarte, Genoveva Cuesta, Fernanda Meira, and Laura Morata made significant contributions to the manuscript. Pedro Puerta-Accalde, Sabina Herrera, and Gemma Sanjuan performed the statistical analysis and made significant contributions to the final
manuscript. Montse Tuset, Pedro Castro, Sergio Prieto-Gonzalez, Josep Mensa, and José Antonio Martínez collaborated on the design of the study and critically reviewed the article. J.M. Nicolas, A. Del Rio, Jordi Vila, Felipe Garcia, Carolina García-Vidal, and Alex Soriano were responsible for the design of the study and made significant contributions to the final version of the article. Alex Soriano, as the corresponding author, answered the reviewers’ questions.

**List of Investigators.** Hospital Clinic of Barcelona COVID-19 Research Group: Infectious Diseases’ Research Group: J. L. Blanco, J. Mallolas, E. Martínez, M. Martínez, J. M. Miró, A. Moreno, M. Solá, A. Ugarte, Ana Gonzalez-Cordón, Montse Laguno, Lorna Leal, John Rojas, Berta Torres, and all the staff members. Medical Intensive Care Unit: S. Fernandez, A. Tellez, F. Fuentes, E. Sancho, M. Ayala. Department of International Health: D. Campubri, M. T. de Alba, M. Fernandez, E. Ferrer, B. Grau, H. Martí, M. Muelas, M. J. Pinazo, N. Rodríguez, M. Roldan, C. Subira, I. Vera, N. Williams, A. Almuedo-Ríerá, J. Muñoz, and all the staff members. Department of Internal Medicine: A. Aldea, M. Camafort, J. Calvo, A. Capdevila, F. Cardellach, I. Carbonell, E. Coloma, A. Foncillas, R. Estruch, M. Felu, J. Fernández-Solá, I. Fuertes, C. Gabara, I. Grafía, A. Ladino, R. López-Alfaro, A. López-Soto, I. Macaya, F. Masanés, A. Matas, M. Navarro, J. Marco-Hernández, L. Miguel, J. C. Milisenda, P. Moreno, J. Naval, D. Nicolás, H. Oberoi, J. Padrosa, S. Prieto-González, M. Pellicé, J. Ribot, O. Rodríguez-Núñez, E. Sacanella, F. Seguí, C. Sierra, A. Tomé, M. Torres, H. Ventosa, C. Zamora-Martínez, and all the staff members. Department of Microbiology: M. Almela, M. Alvarez, J. Bosch, J. Costa, G. Cuesta, B. Fidalgo, J. González, F. Marco, S. Narvaez, C. Pitart, E. Rubio, A. Vergara, M. E. Valls, Y. Zboromyrska and all the staff members. Department of Farmacy: E. López, and all the staff members.

**Disclosures.** Carol García-Vidal has received honoraria for talks on behalf of Gilead Science, MSD, Novartis, Pfizer, Janssen, and Lilly, as well as a grant from Gilead Science and MSD. Laura Morata has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer and Angelini. Pedro Puerta-Alcalde has received honoraria for talks on behalf of Gilead Science and MSD. Montse Tuset has received grants from Janssen, Gilead, ViiV and Merck Sharp and Dohme. Josep Mensa has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Novartis and Angelini. Alex Soriano has received honoraria for talks on behalf of Merck Sharp and Dohme, Pfizer, Novartis, Gilead, Menarini and Angelini as well as grant support from Pfizer and Gilead. Rodrigo Alonso, Ana M Camón, Celia Cardozo, Laia Albiach, Daiana Agüero, M Ángeles Marcos, Juan Ambrosioni, Marta Bodro, Mariana Chumbita, Lorena de la Mora, Nicole García-Pouton, Gerard Dueñas, Marta Hernández-Meneses, Alexy Inciarte, Genoveva Cuesta, Fernanda Meira, Sabina Herrera, Pedro Castro, Sergio Prieto-González, Jose Antonio Martínez, Gemma Sanjuan, Josep María Nicolás, Ana del Río, Jordi Vila and Felipe García have nothing to disclose.

**Compliance with ethics guidelines.** The Institutional Ethics Committee of Hospital Clinic of Barcelona approved the study and, due to the nature of the retrospective data review, waived the need for informed consent from individual patients (HCB/2020/0273). The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments.

**Data availability.** The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons
licensure, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Hopkins J. COVID-19 dashboard: by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [Internet]. https://coronavirus.jhu.edu/map.html. Accessed 14 Aug 2021

2. Fang FC, Benson CA, del Rio C, Edwards KM, Vance GF Jr, Fredricks DN, et al. COVID-19—lessons learned and questions remaining. Clin Infect Dis. 2020;72:ciaa1654.

3. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–24.

4. Simon P, Ho A, Shah MD, Shetgiri R. Trends in mortality from COVID-19 and other leading causes of death among white vs white individuals in Los Angeles County, 2011–2020. JAMA. 2021;326:973–4.

5. Paulo S. Pinheiro, Heidy N. Medina, Zelde Espinel, Erin N. Kobetz and James M. Shultz. New insights into the burden of COVID-19 mortality for U.S. Hispanics and Blacks when examined by country/region of origin: an observational study. Lancet Reg Health-Americas. 2022; 5:100090.

6. Acosta AM, Garg S, Pham H, Whitaker M, Anglin O, O’Halloran A, et al. Racial and ethnic disparities in rates of COVID-19-associated hospitalization, intensive care unit admission, and in-hospital death in the United States From March 2020 to February 2021. Jama Netw Open. 2021;4:e2130479.

7. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, et al. Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: a nationwide cohort study. Plos Med. 2020;17: e1003379.

8. Garcia-Vidal C, Alonso R, Camon AM, Cardozo C, Albiach L, Agüero D, et al. Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. J Antimicrobial Chemother. 2021;76:dkab321.

9. Zhang Q, Bastard P, Liu Z, Pen JL, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570.

10. Bastard P, Rosen LB, Zhang Q, Michaelidis E, Hoffmann H-H, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585.

11. Cruz BH, Alonso F, Alén JC, Pego-Reigosa JM, López-Longo FJ, Galindo-Izquierdo M, et al. Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSE registry). Lupus. 2019;29:27–36.

12. Marks M, Millat-Martinez P, Ouchi D, Roberts CH, Alemanny A, Corbacho-Monné M, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. Lancet Infect Dis. 2021;21:629–36.

13. Ge Y, Martinez L, Sun S, Chen Z, Zhang F, Li F, et al. COVID-19 transmission dynamics among close contacts of index patients with COVID-19. Jama Intern Med. 2021;181:1343–50.

14. Guallar MP, Meiriño R, Donat-Vargas C, Corral O, Jouvé N, Soriano V. Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity. Int J Infect Dis. 2020;97:290–2.

15. Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11:5493.

16. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19—final report. New Engl J Med. 2020;383:1813–26.

17. Abani O, Abbas A, Abbas F, Abbasi S, Abbass H, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–45.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.